Suggestions
Mark Febbraio
Professor and Head of Division at Garvan Institute of Medical Research
Professor Mark Febbraio is a prominent physiologist, academic, and researcher specializing in the fields of exercise, obesity, type 2 diabetes, and cancer. He is the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Program at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Australia. He also serves as a Senior Principal Research Fellow for the National Health and Medical Research Council (NHMRC) and holds leadership roles in biotechnology companies such as N-Gene Pharmaceuticals and Kinomedica.124
Research Focus
- Febbraio's work aims to understand cellular and molecular mechanisms underlying metabolic diseases to develop novel therapies. His research includes studying lipid-induced inflammation, insulin resistance, and exercise-related benefits.
- He has contributed significantly to drug discovery, including developing HSP72 activator BGP-15 to combat insulin resistance and modifying interleukin-6 molecules to mimic exercise benefits without adverse effects.147
Academic Achievements
- He has authored over 280 peer-reviewed papers with over 50,000 career citations and an impressive h-index of 105.24
- Febbraio has received numerous prestigious awards, including the Kellion Award (2017), GSK Award for Research Excellence (2020), and the International Medal from the Society for Endocrinology (2021).46
Career Highlights
- Founder of Celesta Therapeutics and Kinomedica.
- Former Head of Diabetes and Metabolism at the Garvan Institute of Medical Research.
- Member of editorial boards for journals like Diabetes and The American Journal of Physiology Endocrinology & Metabolism.35
Early Life and Sporting Career
Febbraio holds a PhD in Chemistry and Biology from Victoria University. Before his academic career, he was a professional Ironman triathlete, competing internationally, including at the 1989 Ironman World Championships in Hawaii.47
His groundbreaking research bridges academia and industry, aiming to address lifestyle-related diseases through innovative therapeutic approaches.